{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:25:06Z","timestamp":1791498306587,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF#16778"],"award-info":[{"award-number":["MJFF#16778"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["MJFF#16778"],"award-info":[{"award-number":["MJFF#16778"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01185-8","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:37:57Z","timestamp":1764160677000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Interferon gamma stimulates coordinated changes in LRRK2, GCase, and cathepsin activities in idiopathic and genetic Parkinson\u2019s disease monocytes"],"prefix":"10.1038","volume":"11","author":[{"given":"Laura P.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Wallings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Agin-Liebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy N.","family":"Alcalay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mal\u00fa G\u00e1mez","family":"Tansey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Dzamko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"1185_CR1","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41577-022-00684-6","volume":"22","author":"MG Tansey","year":"2022","unstructured":"Tansey, M. G. et al. Inflammation and immune dysfunction in Parkinson disease. Nat. Rev. Immunol. 22, 657\u2013673 (2022).","journal-title":"Nat. Rev. Immunol."},{"key":"1185_CR2","doi-asserted-by":"publisher","first-page":"105700","DOI":"10.1016\/j.nbd.2022.105700","volume":"168","author":"F Weiss","year":"2022","unstructured":"Weiss, F. et al. Immune responses in the Parkinson\u2019s disease brain. Neurobiol. Dis. 168, 105700 (2022).","journal-title":"Neurobiol. Dis."},{"key":"1185_CR3","doi-asserted-by":"publisher","first-page":"S65","DOI":"10.3233\/JPD-223152","volume":"12","author":"E Contaldi","year":"2022","unstructured":"Contaldi, E., Magistrelli, L. & Comi, C. T Lymphocytes in Parkinson\u2019s Disease. J. Parkinsons Dis. 12, S65\u2013S74 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s00401-014-1345-4","volume":"128","author":"V Grozdanov","year":"2014","unstructured":"Grozdanov, V. et al. Inflammatory dysregulation of blood monocytes in Parkinson\u2019s disease patients. Acta Neuropathol. 128, 651\u2013663 (2014).","journal-title":"Acta Neuropathol."},{"key":"1185_CR5","doi-asserted-by":"publisher","first-page":"NS20220063","DOI":"10.1042\/NS20220063","volume":"7","author":"N Dzamko","year":"2023","unstructured":"Dzamko, N. Cytokine activity in Parkinson\u2019s disease. Neuronal Signal 7, NS20220063 (2023).","journal-title":"Neuronal Signal"},{"key":"1185_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41531-023-00449-5","volume":"9","author":"Y Qu","year":"2023","unstructured":"Qu, Y. et al. A systematic review and meta-analysis of inflammatory biomarkers in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 18 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR7","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1093\/brain\/awab156","volume":"144","author":"Q Wang","year":"2021","unstructured":"Wang, Q. et al. The role of gut dysbiosis in Parkinson\u2019s disease: mechanistic insights and therapeutic options. Brain 144, 2571\u20132593 (2021).","journal-title":"Brain"},{"key":"1185_CR8","doi-asserted-by":"publisher","first-page":"S165","DOI":"10.3233\/JPD-213138","volume":"12","author":"J Garcia-Revilla","year":"2022","unstructured":"Garcia-Revilla, J. et al. Inflammatory Animal Models of Parkinson\u2019s Disease. J. Parkinsons Dis. 12, S165\u2013S182 (2022).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR9","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","volume":"44","author":"A Zimprich","year":"2004","unstructured":"Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601\u2013607 (2004).","journal-title":"Neuron"},{"key":"1185_CR10","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","volume":"44","author":"C Paisan-Ruiz","year":"2004","unstructured":"Paisan-Ruiz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson\u2019s disease. Neuron 44, 595\u2013600 (2004).","journal-title":"Neuron"},{"key":"1185_CR11","doi-asserted-by":"publisher","first-page":"eaai7795","DOI":"10.1126\/scitranslmed.aai7795","volume":"10","author":"KY Hui","year":"2018","unstructured":"Hui, K. Y. et al. Functional variants in the LRRK2 gene confer shared effects on risk for Crohn\u2019s disease and Parkinson\u2019s disease. Sci. Transl. Med 10, eaai7795 (2018).","journal-title":"Sci. Transl. Med"},{"key":"1185_CR12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev-genom-082908-150013","volume":"10","author":"J Van Limbergen","year":"2009","unstructured":"Van Limbergen, J., Wilson, D. C. & Satsangi, J. The genetics of Crohn\u2019s disease. Annu Rev. Genomics Hum. Genet 10, 89\u2013116 (2009).","journal-title":"Annu Rev. Genomics Hum. Genet"},{"key":"1185_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom13040612","volume":"13","author":"X Zhang","year":"2023","unstructured":"Zhang, X. & Kortholt, A. LRRK2 Structure-Based Activation Mechanism and Pathogenesis. Biomolecules 13, 612 (2023).","journal-title":"Biomolecules"},{"key":"1185_CR14","doi-asserted-by":"publisher","first-page":"e39132","DOI":"10.1371\/journal.pone.0039132","volume":"7","author":"N Dzamko","year":"2012","unstructured":"Dzamko, N. et al. The IkappaB kinase family phosphorylates the Parkinson\u2019s disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling. PLoS One 7, e39132 (2012).","journal-title":"PLoS One"},{"key":"1185_CR15","doi-asserted-by":"publisher","first-page":"eaan8162","DOI":"10.1126\/scitranslmed.aan8162","volume":"10","author":"T Takagawa","year":"2018","unstructured":"Takagawa, T. et al. An increase in LRRK2 suppresses autophagy and enhances Dectin-1-induced immunity in a mouse model of colitis. Sci. Transl. Med 10, eaan8162 (2018).","journal-title":"Sci. Transl. Med"},{"key":"1185_CR16","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/ni.2113","volume":"12","author":"Z Liu","year":"2011","unstructured":"Liu, Z. et al. The kinase LRRK2 is a regulator of the transcription factor NFAT that modulates the severity of inflammatory bowel disease. Nat. Immunol. 12, 1063\u20131070 (2011).","journal-title":"Nat. Immunol."},{"key":"1185_CR17","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1084\/jem.20170014","volume":"214","author":"W Liu","year":"2017","unstructured":"Liu, W. et al. LRRK2 promotes the activation of NLRC4 inflammasome during Salmonella Typhimurium infection. J. Exp. Med 214, 3051\u20133066 (2017).","journal-title":"J. Exp. Med"},{"key":"1185_CR18","doi-asserted-by":"publisher","first-page":"e202310150","DOI":"10.1083\/jcb.202310150","volume":"224","author":"A Bentley-DeSousa","year":"2025","unstructured":"Bentley-DeSousa, A., Roczniak-Ferguson, A. & Ferguson, S. M. A STING-CASM-GABARAP pathway activates LRRK2 at lysosomes. J. Cell Biol. 224, e202310150 (2025).","journal-title":"J. Cell Biol."},{"key":"1185_CR19","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s11481-020-09909-8","volume":"15","author":"T Ikezu","year":"2020","unstructured":"Ikezu, T. et al. Crohn\u2019s and Parkinson\u2019s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14(+) Blood Monocytes Ex Vivo. J. Neuroimmune Pharm. 15, 794\u2013800 (2020).","journal-title":"J. Neuroimmune Pharm."},{"key":"1185_CR20","doi-asserted-by":"publisher","first-page":"102064","DOI":"10.1016\/j.omtn.2023.102064","volume":"34","author":"RL Wallings","year":"2023","unstructured":"Wallings, R. L. et al. ASO-mediated knockdown or kinase inhibition of G2019S-Lrrk2 modulates lysosomal tubule-associated antigen presentation in macrophages. Mol. Ther. Nucleic Acids 34, 102064 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1185_CR21","doi-asserted-by":"publisher","unstructured":"Salari, M. et al. Human leukocyte antigen in Parkinson\u2019s disease: A systematic review and meta-analysis of risk and clinical attributes. Neurol. Sci. https:\/\/doi.org\/10.1007\/s10072-025-08525-9 (2025).","DOI":"10.1007\/s10072-025-08525-9"},{"key":"1185_CR22","doi-asserted-by":"publisher","first-page":"5577","DOI":"10.4049\/jimmunol.1000548","volume":"185","author":"A Gardet","year":"2010","unstructured":"Gardet, A. et al. LRRK2 is involved in the IFN-gamma response and host response to pathogens. J. Immunol. 185, 5577\u20135585 (2010).","journal-title":"J. Immunol."},{"key":"1185_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41531-017-0010-8","volume":"3","author":"DA Cook","year":"2017","unstructured":"Cook, D. A. et al. LRRK2 levels in immune cells are increased in Parkinson\u2019s disease. NPJ Parkinsons Dis. 3, 11 (2017).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR24","doi-asserted-by":"publisher","first-page":"eabj2658","DOI":"10.1126\/scitranslmed.abj2658","volume":"14","author":"D Jennings","year":"2022","unstructured":"Jennings, D. et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson\u2019s disease. Sci. Transl. Med 14, eabj2658 (2022).","journal-title":"Sci. Transl. Med"},{"key":"1185_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/mds.29297","volume":"38","author":"D Jennings","year":"2023","unstructured":"Jennings, D. et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson\u2019s Disease. Mov. Disord. 38, 386\u2013398 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR26","doi-asserted-by":"publisher","first-page":"e12813","DOI":"10.7554\/eLife.12813","volume":"5","author":"M Steger","year":"2016","unstructured":"Steger, M. et al. Phosphoproteomics reveals that Parkinson\u2019s disease kinase LRRK2 regulates a subset of Rab GTPases. Elife 5, e12813 (2016).","journal-title":"Elife"},{"key":"1185_CR27","doi-asserted-by":"publisher","first-page":"105081","DOI":"10.1016\/j.nbd.2020.105081","volume":"145","author":"T Kuwahara","year":"2020","unstructured":"Kuwahara, T. et al. Roles of lysosomotropic agents on LRRK2 activation and Rab10 phosphorylation. Neurobiol. Dis. 145, 105081 (2020).","journal-title":"Neurobiol. Dis."},{"key":"1185_CR28","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.26562","volume":"31","author":"T Moors","year":"2016","unstructured":"Moors, T. et al. Lysosomal Dysfunction and alpha-Synuclein Aggregation in Parkinson\u2019s Disease: Diagnostic Links. Mov. Disord. 31, 791\u2013801 (2016).","journal-title":"Mov. Disord."},{"key":"1185_CR29","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","volume":"361","author":"E Sidransky","year":"2009","unstructured":"Sidransky, E. et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson\u2019s disease. N. Engl. J. Med 361, 1651\u20131661 (2009).","journal-title":"N. Engl. J. Med"},{"key":"1185_CR30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3390\/jcm9030736","volume":"9","author":"DEC Boer","year":"2020","unstructured":"Boer, D. E. C. et al. Glucocerebrosidase: Functions in and Beyond the Lysosome. J. Clin. Med 9, 736 (2020).","journal-title":"J. Clin. Med"},{"key":"1185_CR31","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls, M. A. et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091\u20131102 (2019).","journal-title":"Lancet Neurol."},{"key":"1185_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13413-w","volume":"10","author":"D Ysselstein","year":"2019","unstructured":"Ysselstein, D. et al. LRRK2 kinase activity regulates lysosomal glucocerebrosidase in neurons derived from Parkinson\u2019s disease patients. Nat. Commun. 10, 5570 (2019).","journal-title":"Nat. Commun."},{"key":"1185_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/s41531-025-01048-2","volume":"11","author":"J Chedid","year":"2025","unstructured":"Chedid, J. et al. Dopamine and cortical neurons with different Parkinsonian mutations show variation in lysosomal and mitochondrial dysfunction. NPJ Parkinsons Dis. 11, 177 (2025).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR34","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13024-024-00779-9","volume":"19","author":"J Jones-Tabah","year":"2024","unstructured":"Jones-Tabah, J. et al. The Parkinson\u2019s disease risk gene cathepsin B promotes fibrillar alpha-synuclein clearance, lysosomal function and glucocerebrosidase activity in dopaminergic neurons. Mol. Neurodegener. 19, 88 (2024).","journal-title":"Mol. Neurodegener."},{"key":"1185_CR35","doi-asserted-by":"publisher","first-page":"892899","DOI":"10.3389\/fncel.2022.892899","volume":"16","author":"RL Wallings","year":"2022","unstructured":"Wallings, R. L. et al. WHOPPA Enables Parallel Assessment of Leucine-Rich Repeat Kinase 2 and Glucocerebrosidase Enzymatic Activity in Parkinson\u2019s Disease Monocytes. Front Cell Neurosci. 16, 892899 (2022).","journal-title":"Front Cell Neurosci."},{"key":"1185_CR36","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41531-022-00297-9","volume":"8","author":"D Ahmadi Rastegar","year":"2022","unstructured":"Ahmadi Rastegar, D. et al. Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages. NPJ Parkinsons Dis. 8, 34 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR37","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.3389\/fimmu.2018.01726","volume":"9","author":"P Sampath","year":"2018","unstructured":"Sampath, P. et al. Monocyte Subsets: Phenotypes and Function in Tuberculosis Infection. Front Immunol. 9, 1726 (2018).","journal-title":"Front Immunol."},{"key":"1185_CR38","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1146\/annurev-immunol-042617-053119","volume":"37","author":"PB Narasimhan","year":"2019","unstructured":"Narasimhan, P. B. et al. Nonclassical Monocytes in Health and Disease. Annu Rev. Immunol. 37, 439\u2013456 (2019).","journal-title":"Annu Rev. Immunol."},{"key":"1185_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1042\/BST20201091","volume":"51","author":"S Strader","year":"2023","unstructured":"Strader, S. & West, A. B. The interplay between monocytes, alpha-synuclein and LRRK2 in Parkinson\u2019s disease. Biochem Soc. Trans. 51, 747\u2013758 (2023).","journal-title":"Biochem Soc. Trans."},{"key":"1185_CR40","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1002\/mds.27601","volume":"34","author":"F Atashrazm","year":"2019","unstructured":"Atashrazm, F. et al. LRRK2-mediated Rab10 phosphorylation in immune cells from Parkinson\u2019s disease patients. Mov. Disord. 34, 406\u2013415 (2019).","journal-title":"Mov. Disord."},{"key":"1185_CR41","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3389\/fnins.2020.00443","volume":"14","author":"RL Wallings","year":"2020","unstructured":"Wallings, R. L., Herrick, M. K. & Tansey, M. G. LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson\u2019s. Front Neurosci. 14, 443 (2020).","journal-title":"Front Neurosci."},{"key":"1185_CR42","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1042\/BST20120119","volume":"40","author":"N Dzamko","year":"2012","unstructured":"Dzamko, N. & Halliday, G. M. An emerging role for LRRK2 in the immune system. Biochem Soc. Trans. 40, 1134\u20131139 (2012).","journal-title":"Biochem Soc. Trans."},{"key":"1185_CR43","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00702-011-0653-2","volume":"118","author":"M Hakimi","year":"2011","unstructured":"Hakimi, M. et al. Parkinson\u2019s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J. Neural Transm. (Vienna) 118, 795\u2013808 (2011).","journal-title":"J. Neural Transm. (Vienna)"},{"key":"1185_CR44","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.3390\/cells9112344","volume":"9","author":"L Iannotta","year":"2020","unstructured":"Iannotta, L. et al. Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues. Cells 9, 2344 (2020).","journal-title":"Cells"},{"key":"1185_CR45","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s00401-021-02325-z","volume":"142","author":"Y Fan","year":"2021","unstructured":"Fan, Y. et al. R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. Acta Neuropathol. 142, 475\u2013494 (2021).","journal-title":"Acta Neuropathol."},{"key":"1185_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.nbd.2014.10.011","volume":"73","author":"A Tsujimura","year":"2015","unstructured":"Tsujimura, A. et al. Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous \u03b1-synuclein fibrils. Neurobiol. Dis. 73, 244\u2013253 (2015).","journal-title":"Neurobiol. Dis."},{"key":"1185_CR47","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.brainres.2009.01.057","volume":"1264","author":"XF Fei","year":"2009","unstructured":"Fei, X. F. et al. Olomoucine inhibits cathepsin L nuclear translocation, activates autophagy and attenuates toxicity of 6-hydroxydopamine. Brain Res 1264, 85\u201397 (2009).","journal-title":"Brain Res"},{"key":"1185_CR48","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.brainres.2011.02.092","volume":"1387","author":"B Xiang","year":"2011","unstructured":"Xiang, B. et al. Cathepsin L is involved in 6-hydroxydopamine induced apoptosis of SH-SY5Y neuroblastoma cells. Brain Res 1387, 29\u201338 (2011).","journal-title":"Brain Res"},{"key":"1185_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neulet.2010.11.068","volume":"489","author":"L Li","year":"2011","unstructured":"Li, L. et al. Parkinson\u2019s disease involves autophagy and abnormal distribution of cathepsin L. Neurosci. Lett. 489, 62\u201367 (2011).","journal-title":"Neurosci. Lett."},{"key":"1185_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.neurobiolaging.2017.09.030","volume":"62","author":"S Xu","year":"2018","unstructured":"Xu, S. et al. Inhibition of cathepsin L alleviates the microglia-mediated neuroinflammatory responses through caspase-8 and NF-\u03baB pathways. Neurobiol. Aging 62, 159\u2013167 (2018).","journal-title":"Neurobiol. Aging"},{"key":"1185_CR51","doi-asserted-by":"publisher","first-page":"412","DOI":"10.3389\/fnmol.2018.00412","volume":"11","author":"A Pi\u0161lar","year":"2018","unstructured":"Pi\u0161lar, A. et al. Upregulation of Cysteine Protease Cathepsin X in the 6-Hydroxydopamine Model of Parkinson\u2019s Disease. Front Mol. Neurosci. 11, 412 (2018).","journal-title":"Front Mol. Neurosci."},{"key":"1185_CR52","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.neuropharm.2016.11.019","volume":"114","author":"A Pi\u0161lar","year":"2017","unstructured":"Pi\u0161lar, A. et al. Inhibition of cathepsin X reduces the strength of microglial-mediated neuroinflammation. Neuropharmacology 114, 88\u2013100 (2017).","journal-title":"Neuropharmacology"},{"key":"1185_CR53","doi-asserted-by":"publisher","first-page":"9322","DOI":"10.1073\/pnas.1500937112","volume":"112","author":"RP McGlinchey","year":"2015","unstructured":"McGlinchey, R. P. & Lee, J. C. Cysteine cathepsins are essential in lysosomal degradation of \u03b1-synuclein. Proc. Natl Acad. Sci. USA 112, 9322\u20139327 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1185_CR54","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.arr.2016.04.010","volume":"32","author":"V Stoka","year":"2016","unstructured":"Stoka, V., Turk, V. & Turk, B. Lysosomal cathepsins and their regulation in aging and neurodegeneration. Ageing Res Rev. 32, 22\u201337 (2016).","journal-title":"Ageing Res Rev."},{"key":"1185_CR55","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/mds.28792","volume":"37","author":"N Omer","year":"2022","unstructured":"Omer, N. et al. Glucocerebrosidase Activity is not Associated with Parkinson\u2019s Disease Risk or Severity. Mov. Disord. 37, 190\u2013195 (2022).","journal-title":"Mov. Disord."},{"key":"1185_CR56","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/mds.29360","volume":"38","author":"JM den Heijer","year":"2023","unstructured":"den Heijer, J. M. et al. A Biomarker Study in Patients with GBA1-Parkinson\u2019s Disease and Healthy Controls. Mov. Disord. 38, 783\u2013795 (2023).","journal-title":"Mov. Disord."},{"key":"1185_CR57","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/mds.26433","volume":"30","author":"N Papagiannakis","year":"2015","unstructured":"Papagiannakis, N. et al. Lysosomal alterations in peripheral blood mononuclear cells of Parkinson\u2019s disease patients. Mov. Disord. 30, 1830\u20131834 (2015).","journal-title":"Mov. Disord."},{"key":"1185_CR58","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41531-023-00517-w","volume":"9","author":"CEG Leyns","year":"2023","unstructured":"Leyns, C. E. G. et al. Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson\u2019s disease. NPJ Parkinsons Dis. 9, 74 (2023).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR59","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/ana.23614","volume":"72","author":"ME Gegg","year":"2012","unstructured":"Gegg, M. E. et al. Glucocerebrosidase deficiency in substantia nigra of parkinson disease brains. Ann. Neurol. 72, 455\u2013463 (2012).","journal-title":"Ann. Neurol."},{"key":"1185_CR60","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13024-015-0010-2","volume":"10","author":"D Chiasserini","year":"2015","unstructured":"Chiasserini, D. et al. Selective loss of glucocerebrosidase activity in sporadic Parkinson\u2019s disease and dementia with Lewy bodies. Mol. Neurodegener. 10, 15 (2015).","journal-title":"Mol. Neurodegener."},{"key":"1185_CR61","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1212\/WNL.0000000000201418","volume":"100","author":"L Oftedal","year":"2023","unstructured":"Oftedal, L. et al. Association of CSF Glucocerebrosidase Activity With the Risk of Incident Dementia in Patients With Parkinson Disease. Neurology 100, e388\u2013e395 (2023).","journal-title":"Neurology"},{"key":"1185_CR62","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/mds.27136","volume":"32","author":"L Parnetti","year":"2017","unstructured":"Parnetti, L. et al. Cerebrospinal fluid \u03b2-glucocerebrosidase activity is reduced in parkinson\u2019s disease patients. Mov. Disord. 32, 1423\u20131431 (2017).","journal-title":"Mov. Disord."},{"key":"1185_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-33921-x","volume":"8","author":"F Atashrazm","year":"2018","unstructured":"Atashrazm, F. et al. Reduced glucocerebrosidase activity in monocytes from patients with Parkinson\u2019s disease. Sci. Rep. 8, 15446 (2018).","journal-title":"Sci. Rep."},{"key":"1185_CR64","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1093\/brain\/awv179","volume":"138","author":"RN Alcalay","year":"2015","unstructured":"Alcalay, R. N. et al. Glucocerebrosidase activity in Parkinson\u2019s disease with and without GBA mutations. Brain 138, 2648\u20132658 (2015).","journal-title":"Brain"},{"key":"1185_CR65","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41531-022-00354-3","volume":"8","author":"M Kedariti","year":"2022","unstructured":"Kedariti, M. et al. LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson\u2019s disease. NPJ Parkinsons Dis. 8, 92 (2022).","journal-title":"NPJ Parkinsons Dis."},{"key":"1185_CR66","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JPD-202508","volume":"11","author":"LP Hughes","year":"2021","unstructured":"Hughes, L. P. et al. Glucocerebrosidase Activity is Reduced in Cryopreserved Parkinson\u2019s Disease Patient Monocytes and Inversely Correlates with Motor Severity. J. Parkinsons Dis. 11, 1157\u20131165 (2021).","journal-title":"J. Parkinsons Dis."},{"key":"1185_CR67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith, L. & Schapira, A. H. V. GBA Variants and Parkinson Disease: Mechanisms and Treatments. Cells 11, 1261 (2022).","journal-title":"Cells"},{"key":"1185_CR68","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.4049\/jimmunol.130.4.1492","volume":"130","author":"TY Basham","year":"1983","unstructured":"Basham, T. Y. & Merigan, T. C. Recombinant interferon-gamma increases HLA-DR synthesis and expression. J. Immunol. 130, 1492\u20131494 (1983).","journal-title":"J. Immunol."},{"key":"1185_CR69","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4049\/jimmunol.140.5.1660","volume":"140","author":"FM Rosa","year":"1988","unstructured":"Rosa, F. M. & Fellous, M. Regulation of HLA-DR gene by IFN-gamma. Transcriptional and post-transcriptional control. J. Immunol. 140, 1660\u20131664 (1988).","journal-title":"J. Immunol."},{"key":"1185_CR70","doi-asserted-by":"publisher","first-page":"832","DOI":"10.3389\/fimmu.2017.00832","volume":"8","author":"NB Crux","year":"2017","unstructured":"Crux, N. B. & Elahi, S. Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?. Front Immunol. 8, 832 (2017).","journal-title":"Front Immunol."},{"key":"1185_CR71","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0165-5728(92)90001-2","volume":"37","author":"RM Ransohoff","year":"1992","unstructured":"Ransohoff, R. M. et al. Monocytes in active multiple sclerosis: intact regulation of HLA-DR density in vitro despite decreased HLA-DR density in vivo. J. Neuroimmunol. 37, 169\u2013176 (1992).","journal-title":"J. Neuroimmunol."},{"key":"1185_CR72","doi-asserted-by":"publisher","first-page":"e2020858118","DOI":"10.1073\/pnas.2020858118","volume":"118","author":"K Farmen","year":"2021","unstructured":"Farmen, K. et al. Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proc. Natl Acad. Sci. USA 118, e2020858118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1185_CR73","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1002\/mds.27815","volume":"34","author":"SK Nissen","year":"2019","unstructured":"Nissen, S. K. et al. Alterations in Blood Monocyte Functions in Parkinson\u2019s Disease. Mov. Disord. 34, 1711\u20131721 (2019).","journal-title":"Mov. Disord."},{"key":"1185_CR74","doi-asserted-by":"publisher","first-page":"eadl1535","DOI":"10.1126\/scitranslmed.adl1535","volume":"16","author":"RL Wallings","year":"2024","unstructured":"Wallings, R. L. et al. The R1441C-Lrrk2 mutation induces myeloid immune cell exhaustion in an age- and sex-dependent manner in mice. Sci. Transl. Med 16, eadl1535 (2024).","journal-title":"Sci. Transl. Med"},{"key":"1185_CR75","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/mds.25300","volume":"28","author":"N Funk","year":"2013","unstructured":"Funk, N. et al. Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson\u2019s disease. Mov. Disord. 28, 392\u2013395 (2013).","journal-title":"Mov. Disord."},{"key":"1185_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/cc8959","volume":"14","author":"OY Kim","year":"2010","unstructured":"Kim, O. Y. et al. Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation. Crit. Care 14, R61 (2010).","journal-title":"Crit. Care"},{"key":"1185_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-015-0180-y","volume":"20","author":"H Vester","year":"2015","unstructured":"Vester, H. et al. HLA-DR expression on monocytes is decreased in polytraumatized patients. Eur. J. Med Res 20, 84 (2015).","journal-title":"Eur. J. Med Res"},{"key":"1185_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/SHK.0b013e318299ebdd","volume":"40","author":"W Tillinger","year":"2013","unstructured":"Tillinger, W. et al. Monocyte human leukocyte antigen-DR expression-a tool to distinguish intestinal bacterial infections from inflammatory bowel disease?. Shock 40, 89\u201394 (2013).","journal-title":"Shock"},{"key":"1185_CR79","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/gut.35.4.511","volume":"35","author":"KR Gardiner","year":"1994","unstructured":"Gardiner, K. R. et al. Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease. Gut 35, 511\u2013516 (1994).","journal-title":"Gut"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01185-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01185-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T14:05:22Z","timestamp":1764165922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01185-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1185"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01185-8","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Nicolas Dzamko is an Associate Editor for npj Parkinson\u2019s Disease, and Malu Tansey is Editor in Chief for npj Parkinson\u2019s Disease, but they both had no involvement in the editorial review or publication decision of this article. All authors declare no other financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"337"}}